Extended Experience with Recombinant a-2b Interferon with OR Without Hepatic Artery Embolization in the Treatment OF Midgut Carcinoid Tumours A preliminary report

References

• Biörck G, Axén O, Thorson A. Unusual cyanosis in a boy with congenital pulmonary stenosis and tricuspid insufficiency. Fatal outcome after angiocardiography. Am Heart J 1952; 44: 143–8
   PubMed Web of Science ®Google Scholar
• Davis Z, Moertel C G, McIlrath DC. The malignant carcinoid syndrome. Surg Gynecol Obstet 1973; 137: 637–44
   PubMedGoogle Scholar
• Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1: 727–40
   PubMed Web of Science ®Google Scholar
• Maton P N, Camilleri M, Grffin G, Allison D J, Hodgson H JF, Chadwick VS. Role of hepatic arterial embolisation in the carcinoid syndrome. Br Med J 1983; 287: 932–5
   PubMed Web of Science ®Google Scholar
• Mårtensson H, Nobin A, Bengmark S, Lunderquist A, Owman T, Sanden G. Embolization of the liver in the management of metastatic carcinoid tumors. J Surg Oncol 1984; 27: 152–8
   PubMed Web of Science ®Google Scholar
• Mitty H A, Warner R RP, Newman L H, Train J S, Parnes IH. Control of carcinoid syndrome with hepatic artery embolization. Radiology 1985; 155: 623–6
   PubMed Web of Science ®Google Scholar
• Stockmann F, Creutzfeldt W. Approach to hepatic involvement by endocrine tumors of the gastrointestinal tract. Semin Liver Dis 1988; 8: 254–62
   PubMed Web of Science ®Google Scholar
• Öberg K, Funa K, Aim G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309: 129–33
   PubMed Web of Science ®Google Scholar
• Hanssen L E, Schrumpf E, Kolbenstvedt A N, Tausjø J, Dolva LØ. Treatment of metastatic midgut carcinoid tumours with recombinant human a 2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 1989; 24: 787–95
   PubMed Web of Science ®Google Scholar
• Froelich J C, Bloomgarten Z T, Oates J A, McGuigan J E, Rabinowitz D. The carcinoid flush. Provocation by pentagas-trin and inhibition by somatostatin. N Engl J Med 1978; 299: 1055–7
   PubMed Web of Science ®Google Scholar
• Kvols L K, Martin J K, Marsh H M, Moertel CG. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 1985; 313: 1229–30
   PubMed Web of Science ®Google Scholar
• Kvols L K, Moertel C G, O'Connell M J, Schutt A J, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663–6
   PubMed Web of Science ®Google Scholar
• Feldman JM. Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem 1986; 32: 840–4
   PubMed Web of Science ®Google Scholar
• Moertel C G, Sauer W G, Dockerty M B, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901–12
   PubMed Web of Science ®Google Scholar
• Theodorsson-Norheim E, Norheim I, Öberg K, et al. Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients. Biochem Biophys Res Commun 1985; 131: 77–83
   PubMed Web of Science ®Google Scholar
• Norheim I, Theodorsson-Norheim E, Brodin E, Öberg K. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986; 63: 605–12
   PubMed Web of Science ®Google Scholar
• Jaffe BM. Prostaglandins and seroton In: nonpeptide diarrheo-genic hormones. World J Surg 1979; 3: 565–78
   PubMedGoogle Scholar
• Roberts W C, Sjoerdsma A. The cardiac disease associated with the carcinoid syndrome (carcinoid heart disease). Am J Med 1964; 36: 5–34
   PubMed Web of Science ®Google Scholar
• Søreide O, Berstad T, Bakka A, et al. Surgical treatment as a principle in patients with advanced carcinoid tumors. Surgery 1991, in press
   Web of Science ®Google Scholar
• Kolmannskog F, Kolbenstvedt A N, Schrumpf E, Hanssen LE. Side-effects and complications following hepatic artery embolization in carcinoid syndrome. Scand J Gastroenterol 1991; 26, in press
   PubMed Web of Science ®Google Scholar
• Hersey P. The evolving role of alpha interferon in the treatment of malignancies. Aust NZ J Med 1986; 16: 425–37
   PubMedGoogle Scholar
• Herberman RB. Cancer therapy by biological response modifiers. Drug Res 1987; 37: 246–50
   Web of Science ®Google Scholar
• Quesada J R, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4: 234–43
   PubMed Web of Science ®Google Scholar
• Bengmark S, Nobin A, Jepsson B, Tranberg KG. Transient repeated dearterialization combined with intraarterial infusion of oncolytic drugs in the treatment of liver tumors. Recent Results Cancer Res 1983; 86: 68–74
   PubMedGoogle Scholar
• Torristi J, Berg C, Bonnem E, Dritschilo A. The combined use of interferon and radiotherapy in cancer management. Semin Oncol 1986; 13: 78–83, Suppl. 2
   PubMed Web of Science ®Google Scholar
• Keane T J, Rider W D, Harwood A R, et al. Whole abdominal radiation in the management of metastatic gastro-intestinal carcinoid tumor. Int J Radiat Oncol Biol Phys 1981; 7: 1519–21
   PubMed Web of Science ®Google Scholar
• Samlowski W E, Eyre H J, Sanse WT. Evaluation of the response of unresectable carcinoid tumors to radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12: 301–5
   PubMed Web of Science ®Google Scholar